• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Holdings Inc. filed SEC Form 8-K: Other Events

    10/7/25 5:23:55 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials
    Get the next $SENS alert in real time by email
    false 0001616543 0001616543 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): October 6, 2025

     

    SENSEONICS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-37717   47-1210911
    (State or Other
    Jurisdiction of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (Address of Principal Executive Office) (Zip Code)

     

    Registrant's telephone number, including area code: (301) 515-7260

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock SENS NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    As previously reported, on October 6, 2025, Senseonics Holdings, Inc. (the “Company”) issued a press release announcing among other things, business updates, including certain preliminary, unaudited financial information for the quarter ended September 30, 2025, including reporting preliminary unaudited revenue of approximately $8.1 million in the third quarter of 2025, an increase of 91% versus the third quarter of 2024, driven by approximately 160% new patient growth in the U.S. over the prior year.

     

    Forward Looking Statements

     

    Any statements in this report about future expectations, plans and prospects for the Company, including the anticipated revenue results for the third quarter of 2025 constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the financial close process in connection with the finalization of the Company’s third quarter 2025 financial statements, as well as the review of such financial statements by the Company’s independent registered public accounting firm and such other factors as are set forth in the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and subsequent reports filed with the Securities and Exchange Commission under the heading "Risk Factors." The forward-looking statements included in this report represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

     

    Preliminary Unaudited Financial Information

     

    The preliminary financial information presented in this report are estimates based on information available to management as of the date of this report, have not been reviewed or audited by the Company’s independent registered public accounting firm and are subject to change. There can be no assurance that the Company’s actual reviewed financial results as of and for the third quarter 2025 will not differ from the preliminary financial information presented in this report. The preliminary financial information presented in this report should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and reviewed by the Company’s independent registered public accounting firm.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 7, 2025 SENSEONICS HOLDINGS, INC.
     
      By: /s/ Rick Sullivan
      Name: Rick Sullivan
      Title: Chief Financial Officer

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    SEC Filings

    View All

    Senseonics Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    10/7/25 5:23:55 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    10/6/25 4:26:37 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    9/30/25 4:01:33 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A was granted 35,714 shares, increasing direct ownership by 2% to 1,694,540 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    10/3/25 4:15:24 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Prince Douglas S was granted 19,673 shares, increasing direct ownership by 2% to 1,107,280 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    10/3/25 4:15:27 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Steven Edelman was granted 31,174 shares, increasing direct ownership by 2% to 1,294,175 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    10/3/25 4:15:20 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Roeder Douglas A bought $37,500 worth of shares (75,000 units at $0.50), increasing direct ownership by 5% to 1,463,087 units (SEC Form 4)

    4/A - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/20/24 5:37:53 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Director Roeder Douglas A bought $135,500 worth of shares (325,000 units at $0.42), increasing direct ownership by 30% to 1,413,087 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/16/24 4:21:25 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Chief Financial Officer Sullivan Frederick T. bought $47,475 worth of shares (124,933 units at $0.38), increasing direct ownership by 5% to 2,478,844 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    12/12/24 7:04:14 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for third quarter and provided a business update. Senseonics generated preliminary unaudited revenue of approximately $8.1 million in the third quarter of 2025, an increase of 91% versus the t

    10/6/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics

    - Agreement with Senseonics to transfer commercial activities would integrate Eversense manufacturing and distribution to accelerate growth PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE:SENS). The companies are targeting to unite Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026, subject to a definitiv

    9/3/25 7:22:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    H.C. Wainwright resumed coverage on Senseonics with a new price target

    H.C. Wainwright resumed coverage of Senseonics with a rating of Buy and set a new price target of $1.10

    6/2/25 8:54:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025. Management will hold a conference call to review the Company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by na

    7/16/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Holdings, Inc. Reports First Quarter Financial Results

    Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.3 million in the first quarter of 2025CMS upda

    5/8/25 4:05:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials